Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

por Bird, Paul, Hall, Stephen, Nash, Peter, Connell, Carol A, Kwok, Kenneth, Witcombe, David, Thirunavukkarasu, Krishan
Publicado 2019

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials

por Landewé, Robert B. M., Connell, Carol A., Bradley, John D., Wilkinson, Bethanie, Gruben, David, Strengholt, Sander, van der Heijde, Désirée
Publicado 2016

Fracture in clinical studies of tofacitinib in rheumatoid arthritis

por Hansen, Karen E., Mortezavi, Mahta, Nagy, Edward, Wang, Cunshan, Connell, Carol A., Radi, Zaher, Litman, Heather J., Adami, Giovanni, Rossini, Maurizio
Publicado 2022

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA...

por Winthrop, Kevin L, Citera, Gustavo, Gold, David, Henrohn, Dan, Connell, Carol A, Shapiro, Andrea B, Shi, Harry, Onofrei, Alina M, Pappas, Dimitrios A, Schulze-Koops, Hendrik
Publicado 2021

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance

por Karpouzas, George A., Szekanecz, Zoltán, Baecklund, Eva, Mikuls, Ted R., Bhatt, Deepak L., Wang, Cunshan, Sawyerr, Gosford A., Chen, Yan, Menon, Sujatha, Connell, Carol A., Ytterberg, Steven R., Mortezavi, Mahta
Publicado 2023

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Ind...

por Wang, Xiaoxing, Dowty, Martin E., Wouters, Ann, Tatulych, Svitlana, Connell, Carol A., Le, Vu H., Tripathy, Sakambari, O’Gorman, Melissa T., Winton, Jennifer A., Yin, Natalie, Valdez, Hernan, Malhotra, Bimal K.
Publicado 2022

Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillanc...

por Balanescu, Andra-Rodica, Citera, Gustavo, Pascual-Ramos, Virginia, Bhatt, Deepak L, Connell, Carol A, Gold, David, Chen, All-Shine, Sawyerr, Gosford, Shapiro, Andrea B, Pope, Janet E, Schulze-Koops, Hendrik
Publicado 2022

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

por Curtis, Jeffrey R, Yamaoka, Kunihiro, Chen, Yi-Hsing, Bhatt, Deepak L, Gunay, Levent M, Sugiyama, Naonobu, Connell, Carol A, Wang, Cunshan, Wu, Joseph, Menon, Sujatha, Vranic, Ivana, Gómez-Reino, Juan J
Publicado 2023

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study...

por van der Heijde, Désirée, Strand, Vibeke, Tanaka, Yoshiya, Keystone, Edward, Kremer, Joel, Zerbini, Cristiano A. F., Cardiel, Mario H., Cohen, Stanley, Nash, Peter, Song, Yeong‐Wook, Tegzová, Dana, Gruben, David, Wallenstein, Gene, Connell, Carol A., Fleischmann, Roy
Publicado 2019

Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

por Dougados, Maxime, Charles-Schoeman, Christina, Szekanecz, Zoltán, Giles, Jon T, Ytterberg, Steven R, Bhatt, Deepak L, Koch, Gary G, Vranic, Ivana, Wu, Joseph, Wang, Cunshan, Kwok, Kenneth, Menon, Sujatha, Connell, Carol A, Yndestad, Arne, Rivas, Jose L, Buch, Maya H
Publicado 2023

Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atheroscler...

por Charles-Schoeman, Christina, Buch, Maya H, Dougados, Maxime, Bhatt, Deepak L, Giles, Jon T, Ytterberg, Steven R, Koch, Gary G, Vranic, Ivana, Wu, Joseph, Wang, Cunshan, Kwok, Kenneth, Menon, Sujatha, Rivas, Jose L, Yndestad, Arne, Connell, Carol A, Szekanecz, Zoltan
Publicado 2023

Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry...

por Kremer, Joel M., Bingham, Clifton O., Cappelli, Laura C., Greenberg, Jeffrey D., Madsen, Ann M., Geier, Jamie, Rivas, Jose L., Onofrei, Alina M., Barr, Christine J., Pappas, Dimitrios A., Litman, Heather J., Dandreo, Kimberly J., Shapiro, Andrea B., Connell, Carol A., Kavanaugh, Arthur
Publicado 2021